Collaboration highlight: MiOXSYS will be used to analyze 1000 semen samples from RUBIC

In 2025, ReproUnion-affiliated researchers started to collaborate with Caerus Biotech to use their MiOXIS system on biological samples from the ReproUnion Biobank & Infertility Cohort (RUBIC). The collaboration is exploring how oxidative stress markers correlate with fertility outcomes in connection with IVF treatments. This will both support the company in its continued clinical validation, as well as the clinicians in their work to better understand and treat infertility.

Despite male factor infertility contributing to roughly 50% of cases, it remains largely under-diagnosed. MiOXSYS is a diagnostics solution that goes beyond standard semen analysis to help inform treatment decisions. The MiOXSYS system can measure oxidative stress in semen samples – a critical factor influencing male infertility. In addition, WHO, ESHRE and the European Association of urology recognizes oxidative stress as one of the key factors affecting reproductive outcomes.

Additional news about the collaboration was published in May 2025.